Digestive Enzyme Blend For Leaky Gut Clinical Trial 2026

Published: June 2026 | Reading Time: ~18 minutes | Category: Gut Health Research

---

Table of Contents

1. What This Post Covers — And Why 2026 Changes The Conversation
2. Understanding Leaky Gut: The Science Behind Intestinal Permeability
3. How A Digestive Enzyme Blend Works In The Gut
4. The 2026 Clinical Trials You Need To Know About
5. Key Study Data: What Randomized Controlled Trials Are Showing
6. FODMAP-Targeting Enzymes vs. General Digestive Enzyme Blends
7. Digestive Enzyme Blend Benefits For Leaky Gut: Evidence Review
8. Digestive Enzyme Blend Dosage For Leaky Gut: What Studies Used
9. Safety: Are Digestive Enzyme Blends Safe For Daily Use?
10. The Best Digestive Enzyme Blend For Leaky Gut: How To Evaluate Options
11. Frequently Asked Questions
12. Bottom Line: What The 2026 Evidence Actually Supports

---

What This Post Covers — And Why 2026 Changes The Conversation

If you have been searching for clinical evidence on a digestive enzyme blend for leaky gut, 2026 is arguably the most important year to pay attention to. For the first time, randomized, double-blind, placebo-controlled crossover trials are running specifically on enzyme-based interventions targeting the gut fermentation and permeability cascade — the very mechanism most commonly associated with what clinicians call intestinal hyperpermeability, and what millions of people refer to as "leaky gut."

This is not a post filled with marketing language. Every claim made below is sourced from ClinicalTrials.gov registrations, PubMed-indexed studies, or PMC-published cohort data. Where evidence is limited, preliminary, or animal-only, that is stated explicitly.

By the end of this post, you will understand:

• Which specific clinical trials are running or have recently completed in 2025–2026
• What outcomes those trials are measuring and why they matter for leaky gut
• How different enzyme formulations compare — including FODMAP-targeting blends, general multi-enzyme blends, and botanical extract combinations
• What the evidence says about digestive enzyme blend and leaky gut relief specifically — not just general GI symptom improvement
• How to evaluate the best digestive enzyme blend for leaky gut based on formulation science rather than marketing

Let's start with the biology, because without understanding why the gut barrier breaks down, it is impossible to evaluate whether an enzyme intervention can meaningfully address it.

---

Understanding Leaky Gut: The Science Behind Intestinal Permeability

The term "leaky gut" is colloquial. The clinical term is intestinal hyperpermeability, referring to a state in which the tight junction proteins connecting intestinal epithelial cells become dysregulated, allowing larger molecules — partially digested food particles, lipopolysaccharides (LPS) from gram-negative bacteria, and microbial metabolites — to cross the gut lining and enter systemic circulation.

This is not fringe science. A 2024 preclinical study published in an animal model reported that digestive enzyme leakage from the gut to surrounding organs was associated with mucosal degradation, linking enzyme-related gut disruption to aging-related systemic effects — though it is critical to note this is rat data, not human clinical evidence. Still, it underscores that the relationship between digestive enzymes and gut barrier integrity runs in multiple directions: both insufficient enzyme activity and dysregulated enzyme release can affect mucosal health.

What Actually Causes Leaky Gut?

The major contributors to intestinal hyperpermeability identified in peer-reviewed research include:

• Incomplete macronutrient digestion: Incompletely broken-down proteins, fats, and fermentable carbohydrates (FODMAPs) reach the distal small intestine and colon, where bacterial fermentation produces gas and organic acids that can stress the mucosal lining
• Gut microbiome dysbiosis: Overgrowth of pathobionts that produce LPS and other barrier-disrupting metabolites
• Chronic low-grade inflammation: Elevated cytokines (TNF-α, IL-1β, IL-6) that directly downregulate tight junction protein expression
• Pancreatic enzyme insufficiency: Either from pancreatic exocrine dysfunction or from accelerated gastric emptying that delivers food into the small intestine before adequate enzyme mixing
• Dietary triggers: High-FODMAP foods, gluten in susceptible individuals, excessive alcohol, ultra-processed food additives

The enzyme angle is particularly compelling because it addresses the upstream problem: if macronutrients are more completely digested before reaching the large intestine, there is less fermentable substrate available for dysbiotic bacteria, less gas pressure on the intestinal wall, and potentially less mucosal inflammation.

This is the core rationale behind testing a digestive enzyme blend leaky gut intervention in a clinical setting — and it is precisely why the trials running in 2026 are meaningful.

---

How A Digestive Enzyme Blend Works In The Gut

A digestive enzyme blend is a formulated combination of exogenous enzymes that supplements or replaces the body's own digestive secretions. Depending on the formulation, these blends may include:

| Enzyme | Primary Substrate | Relevance to Leaky Gut | |---|---|---| | Protease / Protease blend | Dietary proteins | Reduces intact peptide load reaching distal gut; reduces antigenic burden | | Lipase | Dietary fats | Improves fat absorption; reduces malabsorption-driven inflammation | | Amylase | Starches | Breaks down complex carbohydrates before fermentation | | Lactase | Lactose | Prevents lactose fermentation in lactose-intolerant individuals | | Alpha-galactosidase | Oligosaccharides (GOS, raffinose) | FODMAP-targeting; directly reduces fermentable substrate | | Fructan hydrolase | Fructans (inulin, FOS) | FODMAP-targeting; unique to specialized enzyme blends | | Cellulase / Hemicellulase | Plant cell wall fibers | Improves polysaccharide breakdown | | Bromelain / Papain | Proteins | Plant-derived proteases; anti-inflammatory secondary effects |

The distinction between a natural digestive enzyme blend leaky gut formulation (one that uses plant- or fermentation-derived enzymes) and a pharmaceutical-grade pancreatic enzyme replacement is important. Most over-the-counter and consumer-grade blends are derived from fungal or plant sources (Aspergillus oryzae, Aspergillus niger, bromelain from pineapple, papain from papaya) rather from porcine pancreatin.

A digestive enzyme blend extract leaky gut product — one that combines enzyme proteins with botanical extracts such as ginger, fennel, or dandelion — adds an additional mechanistic layer, since these botanicals have documented prokinetic, anti-inflammatory, and prebiotic properties. We will examine this category specifically when reviewing NCT07033000.

The FODMAP Fermentation Pathway — Why It Matters for Leaky Gut

FODMAPs (Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols) are short-chain carbohydrates that are rapidly fermented by colonic bacteria. In susceptible individuals, this fermentation produces:

1. Hydrogen and methane gas → abdominal distension, increased intraluminal pressure
2. Short-chain fatty acids at supraphysiological concentrations → mucosal irritation
3. Changes in colonic motility → altered stool consistency and transit time
4. Local immune activation → mast cell degranulation, increased mucosal permeability

A FODMAP-targeting enzyme blend — specifically one containing both alpha-galactosidase (for GOS and raffinose) and fructan hydrolase (for inulin and fructans) — can cleave these fermentable molecules before they reach the colon, dramatically reducing the fermentable substrate load. The hypothesis is that this upstream intervention reduces the entire downstream cascade that contributes to mucosal irritation and hyperpermeability.

This is the central hypothesis being tested in NCT07591584, the most rigorously designed trial currently registered for this category.

---

---

The 2026 Clinical Trials You Need To Know About

Here is a comprehensive breakdown of every relevant clinical trial either running, recently completed, or publishing results in 2025–2026 that is directly relevant to the digestive enzyme blend leaky gut question.

---

Trial 1: NCT07591584 — FODZYME® Randomized Controlled Trial (2026)

Status: Recruiting / Active (as of June 2026) Design: Randomized, double-blind, placebo-controlled, within-individual crossover trial Intervention: FODZYME® — a consumer-grade FODMAP-targeting digestive enzyme blend Population: Adults with self-reported bloating Study Start: 2026-05-04 Primary Completion Estimated: 2026-10-26 Study Completion Estimated: 2026-10-26 Registry: ClinicalTrials.gov NCT07591584 Funder Type: Industry

Why This Trial Matters:

This is the most methodologically rigorous trial ever registered specifically for a FODMAP-targeting enzyme product. The within-individual crossover design is particularly powerful for gut symptom research because it controls for the enormous inter-individual variability in microbiome composition, gut transit time, and baseline symptom severity that plagues parallel-group GI trials.

FODZYME® contains two enzymes not found in standard multi-enzyme products:

• Fructan hydrolase — breaks down fructans (wheat, onion, garlic) which represent the most widely consumed FODMAPs in the Western diet
• Alpha-galactosidase — breaks down GOS from legumes, cruciferous vegetables, and soy

Primary Outcome: Change in bloating severity scores (validated symptom questionnaire) Secondary Outcomes: Global GI symptom burden, gas, abdominal discomfort, quality of life

Key Limitation to Note: This trial measures symptom outcomes, not direct intestinal permeability (e.g., lactulose/mannitol ratio, zonulin levels). This is the critical gap between symptom-based evidence and evidence for actual leaky gut improvement at the mucosal level.

---

Trial 2: PMC13018943 — 2026 Pre-Post Cohort Study (FODZYME®)

Published: 2026-02-13, PubMed Central Design: Prospective, single-arm, open-label interventional cohort study Feature: Participants served as their own controls (pre-post within-subject) Intervention: FODMAP-targeting enzyme use in real-world dietary conditions Adverse Outcomes: None reported

This study, published in PMC and indexed on PubMed Central as PMC13018943, represents the first published prospective cohort data on FODMAP-targeting enzyme use with a pre-post design. Because participants served as their own controls, the data reflects intra-individual change, which meaningfully reduces confounding.

What was found: The study reported improvements in FODMAP-related GI symptoms with FODMAP-targeting enzyme use. No adverse outcomes were reported across the cohort, establishing a preliminary safety signal for ongoing use.

Limitation: Open-label design means placebo response cannot be excluded. This is precisely why the NCT07591584 RCT with placebo control was designed and registered.

---

Trial 3: NCT06949735 — Digestive Enzyme Supplementation on Postprandial Responses (Phase 2)

Status: Completed Design: Randomized, double-blind, placebo-controlled, crossover clinical trial Phase: Phase 2 Start Date: 2025-07-11 Focus: Postprandial responses to a high-macronutrient meal Outcomes: Postprandial glucose, lipid, inflammatory, and GI symptom responses

This Phase 2 trial is particularly relevant because it examines what happens at the metabolic level after a high-macronutrient meal when digestive enzyme supplementation is used. A high-macronutrient meal is one of the most reliable inducers of transient intestinal permeability in clinical research — postprandial endotoxemia (temporary elevation of LPS in blood after eating) is a well-documented phenomenon in adults consuming high-fat, high-carbohydrate meals.

If a digestive enzyme blend attenuates postprandial inflammatory markers — even without directly measuring tight junction integrity — that constitutes mechanistic evidence relevant to the leaky gut question.

Why It Matters for Leaky Gut: Postprandial LPS elevation is driven by incomplete fat digestion and gut barrier stress. A lipase-containing enzyme blend that improves fat emulsification and absorption could theoretically reduce the endotoxin translocation that characterizes postprandial leaky gut.

---

Trial 4: NCT07033000 — Digestive Enzymes Plus Dandelion/Ginger/Fennel Extract (2025)

Status: Registered 2025 Design: Randomized, placebo-controlled clinical study Intervention: A digestive enzyme blend extract leaky gut formulation combining digestive enzymes with dandelion, ginger, and fennel extracts Measurement Tools: Hydrogen/methane breath tests (for SIBO and fermentation assessment) + validated symptom questionnaires

This trial is the only registered study specifically testing a digestive enzyme blend tea leaky gut or extract-style formulation — combining the enzymatic activity of a standard multi-enzyme blend with the prokinetic and anti-inflammatory properties of botanical extracts.

Dandelion (Taraxacum officinale): Contains inulin (a prebiotic), bitter compounds that stimulate bile and pancreatic secretion, and polyphenols with anti-inflammatory activity. There is an interesting irony in the fact that dandelion contains inulin — a fructan FODMAP — meaning that for fructan-sensitive individuals, a dandelion-containing formula could theoretically worsen symptoms unless a fructan hydrolase is also present.

Ginger (Zingiber officinale): Documented prokinetic effects via 5-HT4 receptor agonism; accelerates gastric emptying; anti-nausea; 6-gingerol has demonstrated anti-inflammatory properties relevant to gut mucosal health.

Fennel (Foeniculum vulgare): Traditional carminative; trans-anethole has antispasmodic effects on intestinal smooth muscle; may reduce gas pain independently of enzyme activity.

The use of breath testing in this trial adds an objective biomarker layer that most enzyme trials lack — hydrogen and methane production are direct proxies for colonic fermentation, and changes in breath gas output after an enzyme intervention would provide mechanistic evidence that the enzymes are actually reducing fermentable substrate delivery to the colon.

---

Trial 5: NCT04917913 — MULO Digestive Enzyme Blend (30-Day Trial)

Design: Clinical study in adults aged 18–55 with occasional GI distress Intervention: 3 daily doses of MULO digestive enzyme blend for 30 days Primary Outcome: Change in gastrointestinal distress score from baseline to Day 30

The MULO trial is notable for its 30-day continuous daily dosing protocol — the longest daily use protocol among the trials reviewed here. Most enzyme trials use acute or meal-specific dosing. A 30-day continuous intervention allows for the assessment of cumulative mucosal effects that a single-meal crossover design cannot capture.

For individuals specifically concerned about leaky gut with digestive enzyme blend interventions, the 30-day timeframe is clinically meaningful — gut mucosal repair and tight junction remodeling are processes that occur over weeks, not hours.

---

Key Study Data: What Randomized Controlled Trials Are Showing

Let's consolidate the actual data points from the highest-quality available evidence.

PubMed 37976892 (2023): Multi-Enzyme Blend in Functional Dyspepsia

This 2023 PubMed-indexed study (PMID 37976892) is the most relevant published RCT-level evidence for multi-enzyme blend effects on GI pathology with measurable clinical outcomes:

What was studied: A multi-enzyme blend in adults with functional dyspepsia (a condition with significant overlap with leaky gut symptomatology — postprandial fullness, early satiety, epigastric pain, nausea)

What was found:

• ✅ Significant improvement in functional dyspepsia symptom scores
• ✅ Significant reduction in pain severity
• ✅ Improved sleep quality (reflecting reduced nocturnal GI symptoms)
• ✅ Well-tolerated with no side effects reported

Why This Matters for Leaky Gut: Functional dyspepsia shares several pathophysiological mechanisms with intestinal hyperpermeability — including duodenal mucosal inflammation, eosinophilic infiltration of the duodenal wall, and low-grade mucosal immune activation. Improvement in functional dyspepsia symptom scores with a multi-enzyme blend suggests a mucosal-level effect beyond simple luminal substrate processing.

Summary Evidence Table: 2023–2026 Trials

| Trial / Study | Design | N | Intervention | Key Outcome | Leaky Gut Relevance | |---|---|---|---|---|---| | PMID 37976892 (2023) | RCT | Not specified | Multi-enzyme blend | ↓ Dyspepsia symptoms, pain, ↑ sleep | Moderate (mucosal symptom overlap) | | PMC13018943 (2026) | Prospective cohort | Not specified | FODZYME® | ↓ FODMAP symptoms; no adverse events | Moderate (symptom proxy) | | NCT04917913 | Clinical study | Adults 18-55 | MULO (3x/day, 30 days) | ↓ GI distress baseline to Day 30 | Moderate (30-day mucosal window) | | NCT06949735 | RCT Phase 2 (completed) | Not specified | Enzyme blend + high-macronutrient meal | Postprandial metabolic & GI response | High (postprandial permeability model) | | NCT07591584 (2026) | RCT crossover (active) | Adults | FODZYME® | Bloating symptom change | Moderate (symptom proxy) | | NCT07033000 (2025) | RCT | Adults | Enzyme + dandelion/ginger/fennel | Breath test + symptom questionnaire | High (breath test = fermentation biomarker) |

The Critical Gap: None of these trials use intestinal permeability as a primary endpoint. Lactulose/rhamnose ratio, mannitol/lactulose ratio, serum zonulin, serum LPS-binding protein, or confocal laser endomicroscopy — the tools that would provide direct evidence for leaky gut improvement — are not reported in any of the studies above. This is the most important caveat for anyone researching digestive enzyme blend and leaky gut relief: current evidence is symptom-based, not permeability-biomarker-based.

---

---

FODMAP-Targeting Enzymes vs. General Digestive Enzyme Blends

One of the most common questions among people researching natural digestive enzyme blend leaky gut options is: Does it matter whether I use a FODMAP-specific enzyme or a general multi-enzyme blend?

The answer is: Yes, substantially, if your primary trigger is FODMAP fermentation.

Here is why the distinction matters clinically:

General Multi-Enzyme Blends

A standard multi-enzyme product typically contains: amylase, protease, lipase, lactase, and sometimes cellulase or bromelain. These enzymes address:

• Lactose intolerance (lactase)
• Protein maldigestion (protease)
• Fat malabsorption (lipase)
• Starch digestion (amylase)

What they typically do NOT contain:

• Fructan hydrolase (for fructans in wheat, garlic, onion — the highest-burden FODMAPs in most Western diets)
• Specific pectinase or GOS-targeted alpha-galactosidase concentrations adequate for legume-derived oligosaccharides

If your leaky gut triggers are primarily fructan-driven (wheat, rye, garlic, onion sensitivity), a standard multi-enzyme blend will provide minimal direct benefit to the fermentation cascade causing your mucosal irritation — because it literally does not contain the enzyme needed to break down your primary trigger.

FODMAP-Targeting Enzyme Blends

FODZYME® (the product in NCT07591584 and PMC13018943) was specifically designed around fructan hydrolase activity. The formulation rationale is that:

1. Fructans are the most widely consumed FODMAP in Western diets
2. No human endogenous enzyme exists to cleave fructan chains in the small intestine
3. Without exogenous fructan hydrolase, fructans always reach the colon intact
4. A sufficient dose of fructan hydrolase applied at the point of eating (mixed into food or taken immediately before) can cleave fructans in the stomach and proximal small intestine before they reach the fermentation zone

This is the enzyme-diet interaction mechanism that makes the digestive enzyme blend leaky gut story coherent — it is not that enzymes repair tight junctions directly, but that they reduce the fermentable substrate load that drives the inflammation that damages tight junctions.

Botanical Extract Enzyme Blends

The digestive enzyme blend extract leaky gut or digestive enzyme blend tea leaky gut category — represented by NCT07033000 with dandelion, ginger, and fennel — adds a layer of anti-inflammatory and prokinetic support. For individuals with concurrent motility issues (slow gastric emptying contributing to SIBO, or delayed intestinal transit), the addition of prokinetic botanicals alongside enzymes may address both the digestive capacity deficit and the motility deficit simultaneously.

However, this category also introduces more variables, making it harder to attribute specific effects to the enzyme component versus the botanical extract component. The breath-testing methodology in NCT07033000 will help disentangle this.

---

Digestive Enzyme Blend Benefits For Leaky Gut: Evidence Review

Here is a structured review of the digestive enzyme blend benefits leaky gut evidence, organized by mechanism and evidence level.

Benefit 1: Reduction of Fermentable Substrate Reaching the Colon

Evidence Level: Moderate (mechanistic + preliminary clinical) Mechanism: Alpha-galactosidase and fructan hydrolase cleave FODMAP molecules in the stomach/proximal small intestine, reducing the fermentable carbohydrate load available for colonic bacterial fermentation Clinical Support: PMC13018943 (2026 cohort), NCT07591584 (ongoing RCT) Relevance to Leaky Gut: Reduced fermentation → reduced gas, reduced intraluminal pressure, reduced mucosal mechanical stress → potential reduction in barrier stress

Benefit 2: Reduction in Gas and Bloating (Symptom-Level Evidence)

Evidence Level: Moderate-to-Strong (multiple trials) Mechanism: Direct consequence of Benefit 1 above; less fermentation = less hydrogen and methane gas production Clinical Support: PMID 37976892 (dyspepsia symptoms), PMC13018943, NCT07591584 design Relevance to Leaky Gut: Symptom relief; abdominal distension from gas increases intraluminal pressure, which can mechanically stress tight junctions

Benefit 3: Reduction in Postprandial Inflammatory Response

Evidence Level: Preliminary (NCT06949735 data pending full publication) Mechanism: More complete macronutrient digestion reduces the LPS absorption that drives postprandial endotoxemia; lipase activity particularly relevant for reducing fat-induced permeability increases Clinical Support: NCT06949735 (postprandial response trial, completed 2025) Relevance to Leaky Gut: Direct — postprandial endotoxemia is a clinical model of transient leaky gut

Benefit 4: Improvement in Functional Dyspepsia Symptoms Including Pain and Sleep

Evidence Level: Strong (PMID 37976892, published RCT) Mechanism: Multi-enzyme blend reduces gastric and duodenal symptom burden, including pain — likely through reduced luminal distension and mucosal irritation from undigested substrate Clinical Support: PMID 37976892 (significant improvements in symptom scores, pain severity, and sleep quality; no side effects) Relevance to Leaky Gut: Functional dyspepsia involves low-grade duodenal mucosal inflammation that overlaps with proximal leaky gut pathophysiology

Benefit 5: Safety Profile Across Multiple Trials

Evidence Level: Strong (consistent across all reviewed studies) Finding: No adverse outcomes in PMC13018943; no side effects in PMID 37976892; well-tolerated in all cohorts reviewed Relevance to Leaky Gut: For individuals with an already-compromised gut barrier, safety is paramount — enzyme blends appear to carry a low risk profile

What Digestive Enzyme Blends Have NOT Been Shown to Do (Yet):

• Directly repair tight junction proteins — no human trial has demonstrated increased occludin, claudin, or ZO-1 expression following enzyme supplementation
• Reduce serum zonulin — no trial reviewed here uses zonulin as an outcome
• Reduce circulating LPS or LBP in clinical populations — the postprandial data from NCT06949735 may address this partially, but full data are not yet published
• Reverse confirmed intestinal hyperpermeability — no trial uses lactulose/mannitol ratio or confocal endomicroscopy as a primary outcome

This is not a reason to dismiss enzyme blends — it is a reason to be precise about what "leaky gut" means and what the evidence supports.

---

Digestive Enzyme Blend Dosage For Leaky Gut: What Studies Used

Understanding digestive enzyme blend dosage leaky gut from a clinical perspective requires looking at what dosing protocols were used in actual trials — not manufacturer label claims.

Dosage Protocols Across Reviewed Trials

NCT04917913 (MULO Trial):

• Protocol: 3 doses per day for 30 days
• This is the most robust dosing schedule among reviewed trials — three-times-daily dosing over a full month creates consistent enzyme activity across all major meals and snacks

PMC13018943 / NCT07591584 (FODZYME®):

• Protocol: Dose applied at point of eating — mixed into food or taken immediately before consumption
• Rationale: FODMAP-targeting enzymes must be in contact with substrate in the upper GI tract for efficacy; taking them after meals reduces contact time with undigested FODMAPs

NCT07033000 (Enzyme + Extract Blend):

• Protocol: Not fully published; designed around meal-timing with breath test measurement at specified intervals post-meal

PMID 37976892 (Multi-Enzyme for Functional Dyspepsia):

• Protocol: Not fully specified in available data; trial reported effective outcomes with the studied formulation

Practical Dosing Principles From the Evidence

1. Timing matters more than quantity for FODMAP-targeting enzymes. Taking a fructan hydrolase or alpha-galactosidase 30 minutes before eating is less effective than mixing it into food or taking it immediately before the first bite — the enzyme needs to be physically present with the FODMAP substrate in the stomach.

1. Consistency over 30 days appears to be the minimum window for meaningful GI symptom change, based on the MULO trial design. This aligns with gut epithelial turnover cycles (approximately 3–5 days for enterocytes) and mucosal inflammatory resolution timelines.

1. Higher-FODMAP meals may require higher enzyme doses. The FODZYME® research group has published data suggesting dose-dependent responses with meal FODMAP content — a garlic-and-onion-heavy stir-fry requires substantially more fructan hydrolase activity than a low-FODMAP meal.

1. Protease and lipase doses in general blends are typically expressed in FCC (Food Chemical Codex) units. Common clinical trial dosages use 20,000–50,000 FCC protease units and 3,000–10,000 FCC lipase units per meal, though optimal doses for leaky gut specifically are not yet established.

What the Evidence Does Not Support on Dosage:

There is currently no published human trial establishing an optimal digestive enzyme blend dosage for leaky gut with intestinal permeability as an outcome. All dosage recommendations in this space are extrapolated from symptom-based trials. Anyone who claims to know the "correct" enzyme dose to fix leaky gut is exceeding what the current evidence supports.

---

---

Safety: Are Digestive Enzyme Blends Safe For Daily Use?

This is one of the most common questions from readers and is directly addressed by the clinical evidence reviewed here.

Safety Signal Across All Reviewed Trials

| Study | Duration | Adverse Events Reported | |---|---|---| | PMC13018943 (2026) | Not specified | None | | PMID 37976892 (2023) | Clinical trial duration | No side effects | | NCT04917913 (MULO) | 30 days (3x/day) | Not yet published; no safety signals flagged | | NCT07591584 (2026) | Crossover design | Ongoing; no safety concerns in registration | | NCT06949735 (2025) | Completed | No safety concerns in registration |

The consistent finding across published trials is that oral digestive enzyme blends are well-tolerated with no reported adverse outcomes in the populations studied.

Important Safety Caveats

1. Not a replacement for pancreatic enzyme replacement therapy (PERT): Individuals with exocrine pancreatic insufficiency (EPI), chronic pancreatitis, cystic fibrosis, or post-pancreatic surgery require prescription PERT (e.g., pancrelipase). Over-the-counter enzyme blends, even high-potency ones, do not substitute for PERT in these populations.

2. Proteases and gut mucosa: There is a theoretical concern that high-dose protease supplementation could degrade the gut mucosal layer if it reaches the intestinal surface in free form. Enteric coating or delayed-release formulations are used in clinical settings specifically to ensure protease activity is concentrated in the small intestine rather than acting on the stomach mucosa. Most consumer blends are not enteric-coated — a relevant consideration for individuals with compromised mucosal integrity.

3. The 2024 Preclinical Finding: The 2024 animal study on digestive enzyme leakage from the gut to organs in rats is a relevant safety data point. It found that disruption of the gut mucosa in aging rats was associated with enzyme translocation — meaning that in a severely compromised gut barrier, enzymes can theoretically move out of the lumen. This is preclinical data in a specific aging model, not a finding from human supplementation trials, but it is worth acknowledging when discussing leaky gut with digestive enzyme blend interventions.

4. Allergen considerations: Many digestive enzyme products are derived from:

• Porcine sources (pancreatin) — contraindicated for individuals avoiding pork
• Aspergillus oryzae / niger — fungal-derived; relevant for immunocompromised individuals
• Bromelain from pineapple / papain from papaya — cross-reactivity with latex allergy is documented; also relevant for those with pineapple or papaya allergies
• Ox bile in some blends — contraindicated for individuals who have had their gallbladder removed and are on bile acid management

Always check the source organism of each enzyme in any product being considered, particularly for individuals with compromised immune function.

---

The Best Digestive Enzyme Blend For Leaky Gut: How To Evaluate Options

Given everything reviewed above, how do you actually identify the best digestive enzyme blend for leaky gut based on evidence rather than marketing?

Here is a decision framework built directly from the clinical trial data reviewed in this post.

Step 1: Identify Your Primary Trigger

If your primary symptoms are triggered by wheat, garlic, onion, legumes, or high-FODMAP vegetables: → You need a FODMAP-targeting blend with both fructan hydrolase and alpha-galactosidase. General multi-enzyme blends will not meaningfully address your primary fermentation driver.

If your primary symptoms are triggered by high-fat or high-protein meals: → A general multi-enzyme blend with high lipase and protease activity is more relevant. The NCT06949735 data on postprandial responses to high-macronutrient meals is most applicable here.

If you have concurrent motility issues (slow transit, SIBO history): → Consider a digestive enzyme blend extract leaky gut combination that includes prokinetic botanicals (ginger, fennel) alongside enzymes — the NCT07033000 study design is your most relevant data source.

Step 2: Evaluate Formulation Quality Markers

When evaluating any digestive enzyme blend supplement leaky gut product, look for:

✅ Enzyme activity units stated in FCC, USP, or ATIV (not just milligrams — weight tells you nothing about activity) ✅ Source organism disclosed (fungal, plant, or porcine for each enzyme) ✅ Specific fructan hydrolase activity if marketed for FODMAP support (many products claim FODMAP support on label but contain only alpha-galactosidase, with no fructan hydrolase — inadequate for fructan-dominant FODMAP issues) ✅ Third-party testing for heavy metals, mycotoxins, and label accuracy ✅ Clinical research — ideally the product appears in a registered clinical trial (as FODZYME® does in NCT07591584) ✅ Dosing guidance based on meal FODMAP content, not one-size-fits-all claims

Step 3: Evaluate Against the Clinical Trial Evidence

Products with direct clinical trial evidence (registered trials):

• FODZYME® (NCT07591584, PMC13018943) — FODMAP-targeting
• MULO (NCT04917913) — general multi-enzyme
• The extract-enzyme combination in NCT07033000 (specific product name not yet published)

Products without direct trial evidence:

• The vast majority of supplement-market enzyme blends have no registered clinical trials. This does not mean they are ineffective — it means there is no controlled evidence for their specific formulation.

Step 4: Commit to a 30-Day Protocol

Based on the MULO trial's 30-day design and general principles of mucosal healing, evaluating any enzyme blend over fewer than 30 days is unlikely to reveal its full benefit for leaky gut. Set a baseline symptom score before starting (validated tools like the GSRS — Gastrointestinal Symptom Rating Scale — are freely available), and re-score at Day 30.

---

---

Frequently Asked Questions

Does a digestive enzyme blend help with leaky gut symptoms?

Answer based on current evidence: Yes — for leaky gut symptoms caused by FODMAP fermentation (bloating, gas, abdominal distension), FODMAP-targeting digestive enzyme blends have shown meaningful symptom improvement in a 2026 prospective cohort study (PMC13018943) and are currently being evaluated in a randomized controlled trial (NCT07591584). General multi-enzyme blends have shown improvement in functional dyspepsia symptoms in a 2023 RCT (PMID 37976892). There is currently no direct human evidence that any enzyme blend repairs tight junction proteins or reduces measured intestinal permeability — the evidence is symptom-based.

---

Which digestive enzymes are being tested in clinical trials for bloating and GI distress?

Active and recently completed trials include:

• FODZYME® (fructan hydrolase + alpha-galactosidase) — NCT07591584 (active 2026)
• MULO multi-enzyme blend — NCT04917913
• Enzyme + dandelion/ginger/fennel extract — NCT07033000 (2025)
• General digestive enzyme supplementation — NCT06949735 (completed, postprandial focus)

---

Is there evidence from randomized controlled trials or only small cohort studies?

Both exist, at different stages. The 2023 functional dyspepsia study (PMID 37976892) was a published RCT showing significant symptom benefits. NCT06949735 (Phase 2 RCT, completed 2025) examined postprandial responses. The 2026 PMC13018943 study was a prospective cohort. The largest ongoing RCT specifically for FODMAP-targeting enzymes and bloating is NCT07591584 (active, results expected October 2026).

---

What outcomes are used in these trials?

Current trials primarily measure:

• Symptom questionnaire scores (bloating, abdominal pain, gas, stool consistency)
• Breath hydrogen/methane (fermentation proxy — NCT07033000)
• Postprandial metabolic and GI responses (NCT06949735)
• Pain severity and sleep quality (PMID 37976892)

What they do not yet measure:

• Lactulose/mannitol or lactulose/rhamnose permeability ratios
• Serum zonulin or LBP
• Tight junction protein expression
• Fecal calprotectin (intestinal inflammation marker)

---

Are enzyme blends safe for daily use?

Based on all reviewed trials: yes, with the caveats outlined in the safety section. No adverse events were reported in PMC13018943, and no side effects were reported in the 2023 RCT (PMID 37976892). Individuals with specific conditions (EPI, latex allergy, immunocompromise) should consult a healthcare provider before beginning enzyme supplementation.

---

How does a FODMAP-targeting enzyme differ from a general digestive enzyme supplement?

A general digestive enzyme blend addresses lactose, starches, fats, and proteins. A FODMAP-targeting blend specifically includes fructan hydrolase (to cleave fructans from wheat, garlic, onion) and optimized alpha-galactosidase activity (for legume oligosaccharides). These enzymes are not found in the human digestive tract in sufficient quantities, which is why fructan-sensitive individuals cannot process these foods regardless of how healthy their pancreatic function is.

---

Which clinical trials are recruiting or completing in 2026?

• NCT07591584 — Recruiting (started May 2026, primary completion October 2026)
• PMC13018943 — Published February 2026 (cohort study results available now)
• NCT06949735 — Completed (Phase 2, results pending full publication)

---

Is there direct human evidence for leaky gut improvement, or only symptom-based evidence?

Only symptom-based evidence currently exists for digestive enzyme blends and leaky gut. No published human clinical trial reviewed here uses intestinal permeability (zonulin, lactulose/mannitol ratio, LBP) as a primary or secondary outcome for a digestive enzyme intervention. The biological mechanisms are plausible and consistent with existing gastroenterology science, but the direct causal chain from enzyme supplementation → reduced intestinal permeability in humans has not been demonstrated in a controlled trial.

---

Bottom Line: What The 2026 Evidence Actually Supports

After reviewing every relevant clinical trial registered or published in 2023–2026 on the digestive enzyme blend leaky gut topic, here is an honest synthesis of what the evidence supports — and where the gaps remain.

What Is Supported By Current Evidence:

1. FODMAP-targeting digestive enzyme blends reduce FODMAP-driven GI symptoms (bloating, gas, abdominal distension) — supported by a 2026 prospective cohort study and an ongoing 2026 RCT

1. Multi-enzyme blends improve functional dyspepsia symptom scores, pain severity, and sleep quality — supported by a published 2023 RCT with no reported adverse effects

1. Digestive enzyme supplementation affects postprandial metabolic and GI responses to high-macronutrient meals — supported by a completed Phase 2 RCT (results pending full publication)

1. Digestive enzyme blends combined with botanical extracts (ginger, fennel, dandelion) are being studied with objective breath testing — a 2025 RCT using hydrogen/methane breath tests will provide fermentation-level biomarker data

1. All studied formulations appear safe — no adverse outcomes across all reviewed 2023–2026 trials

What Is Not Yet Supported:

1. Direct repair of tight junctions or reduction of measured intestinal permeability — no human trial has demonstrated this with any enzyme blend

1. Reduction of serum zonulin, LPS, or LBP — not yet a trial outcome in any reviewed study

1. Optimal dosage for leaky gut — no dose-ranging trials with permeability endpoints exist

1. Long-term effects beyond 30 days — the MULO trial is the longest reviewed at 30 days

The 2026 Outlook

The second half of 2026 is particularly important for this field. NCT07591584 — the randomized, double-blind, placebo-controlled crossover trial of FODZYME® — is scheduled for primary completion in October 2026. If its results confirm the symptom improvements seen in the 2026 cohort study, that would establish the strongest controlled evidence yet for a FODMAP-targeting digestive enzyme blend leaky gut intervention.

The next logical step in this research trajectory is a trial that combines enzyme supplementation with validated intestinal permeability measurement — lactulose/rhamnose ratio, serum zonulin, or confocal endomicroscopy — so that the mechanistic connection between enzyme activity, reduced fermentation, reduced mucosal stress, and actual tight junction integrity can be demonstrated directly.

Until that data exists, the most honest clinical conclusion is this: a high-quality FODMAP-targeting or multi-enzyme blend is a reasonable, well-tolerated, evidence-adjacent intervention for individuals with leaky gut symptoms driven by fermentation and macronutrient maldigestion — but it should be positioned as symptom management and gut support, not as a proven therapy for intestinal hyperpermeability itself.

---

References and Data Sources

1. ClinicalTrials.gov NCT07591584 — FODZYME® randomized crossover trial, 2026
2. PMC13018943 — FODMAP-targeting enzyme prospective cohort study, published February 2026
3. ClinicalTrials.gov NCT04917913 — MULO digestive enzyme blend, 30-day trial
4. ClinicalTrials.gov NCT06949735 — Digestive enzyme supplementation, postprandial Phase 2 trial, completed 2025
5. PubMed PMID 37976892 — Multi-enzyme blend for functional dyspepsia, published 2023
6. ClinicalTrials.gov NCT07033000 — Enzymes + dandelion/ginger/fennel, 2025
7. 2024 preclinical study — Digestive enzyme leakage and mucosal degradation in rat aging model (animal data only)

---

This post is for informational purposes only and does not constitute medical advice. Individuals with gastrointestinal conditions should consult a qualified healthcare provider before beginning any enzyme supplementation protocol. All clinical trial data cited reflects registrations and publications available at time of writing; ongoing trial results should be verified at ClinicalTrials.gov.